Signaling pathways in human osteoclasts differentiation: ERK1/2 as a key player

Area of Science:

• Cell Biology
• Molecular Signaling
• Bone Metabolism

Background:

• Osteoclast differentiation is crucial for bone remodeling but poorly understood in humans.
• Key signaling pathways like Ras/PI3K/Akt/mTOR, Ras/Raf/MEK1/2/ERK1/2, calcium-PKC, and p38 are implicated but their specific roles in human osteoclastogenesis require elucidation.

Purpose of the Study:

• To investigate the roles of Ras/PI3K/Akt/mTOR, Ras/Raf/MEK1/2/ERK1/2, calcium-PKC, and p38 signaling pathways in human osteoclast differentiation.
• To compare the effects of pathway inhibition in healthy individuals versus patients with neurofibromatosis 1 (NF1).

Main Methods:

• Human peripheral blood mononuclear cells from healthy donors and NF1 patients were differentiated into osteoclasts.
• Osteoclast differentiation was assessed using tartrate-resistant acid phosphatase 5B (TRAP5b) staining.
• Specific signaling pathway inhibitors were used, and Western blot analysis assessed protein phosphorylation (e.g., ERK1/2).

Main Results:

• Inhibition of most pathways decreased osteoclast number and F-actin ring formation.
• p38 pathway inhibition paradoxically increased osteoclast numbers in human cells, contrasting with murine studies, but did not enhance bone resorption.
• Ras inhibitor FTS showed differential effects in control versus NF1 samples; MEK, PI3K, and mTOR inhibition significantly reduced osteoclast numbers in NF1 samples but not controls.
• ERK1/2 phosphorylation levels correlated with osteoclast numbers.

Conclusions:

• Human osteoclastogenesis is regulated by interconnected signaling pathways.
• Findings underscore significant differences between murine and human osteoclast biology.
• Specific pathways (MEK, PI3K, mTOR) are critical for osteoclast differentiation in NF1, suggesting targeted therapeutic potential.